UiPath shares sees a jump — What is fueling the stock rise

Traders Union
All News
Financial News
UiPath rises 3.52% today to $11.46

Highlights

UiPath is set to report Q4 2026 earnings, with consensus estimating $0.25 EPS on $464.8 million revenue after recent 16% growth.
The company broadened its automation portfolio through WorkFusion acquisition and launched AI healthcare tools aimed at record and claims optimization.
Technical outlook remains bearish, with PATH expected to trade sideways between $9.12 and $10.77 and low breakout probability.

Earnings anticipation and AI expansion drive optimism ahead of results

UiPath is scheduled to release its Q4 2026 earnings after the close on March 11, with analysts expecting earnings of $0.25 per share and revenue of $464.814 million. The company has launched new agentic AI tools for healthcare automation at the ViVE 2026 conference, targeting improvements in medical records and claims processing. UiPath also expanded its automation portfolio with the acquisition of WorkFusion, while most recent quarterly revenue was reported at $411.11 million, a 15.9% year-over-year increase.

Anton Kharitonov, expert at Traders Union, sees UiPath’s recent price action as technically fragile. He notes that staying below both the MA-50 and MA-200 points to ongoing medium- and long-term weakness. Kharitonov highlights mixed momentum signals, with the MACD and ADX indicating a dominant bearish trend. He remains skeptical about the impact of new AI tools or acquisitions, as revenue growth has yet to ignite price optimism. "The technical setup and lack of strong buying confirm my cautious outlook for PATH — further declines look likely unless key resistance levels break convincingly."

Viktoras Karapetjanc, expert at Traders Union, believes the company’s fundamentals remain strong despite recent technical pressure. He notes that expanding with WorkFusion and leading in healthcare automation supports future growth. Karapetjanc points out that Q4 earnings and robust year-over-year revenue gains show sustainable progress. He remains upbeat, highlighting opportunities as the market digests PATH’s innovations. "The bullish structure remains intact — I expect continued expansion in automation to drive upside beyond current resistance."

Mixed momentum and overbought signals amid resistance at Ichimoku Kijun

The nearest dynamic resistance is at the Ichimoku Kijun ($12.24), with medium-term resistance at the MA-50, and support established at the MA-20. Daily momentum is mixed: MACD shows strong selling, ADX points to a bearish bias, but RSI and CCI remain near neutral-to-sell levels. Stoch RSI signals overbought conditions, as intraday buyers gain some ground, while the Awesome Oscillator remains neutral, not confirming a trend change. Volatility is moderate, with the price near session highs and underlying signals suggesting caution due to divergence between momentum and oscillators.

Previously it was reported that UiPath Inc. is experiencing short-term buying strength, trading above its 20-day moving average but remaining below longer-term averages, with technical indicators such as the MACD and ADX reflecting prevailing bearish momentum and an RSI below 50 signaling a lack of oversold conditions. Immediate resistance is identified near $12.24, while the stock is expected to consolidate between support at $10.50 and resistance at $12.50 in the near term, as medium-term momentum remains weak despite intraday gains.

Source of Data: PATH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.